What Noumed Life Sciences does

Noumed Life Sciences Limited is a UK-based pharmaceutical company founded in 2013 and headquartered in Maidenhead, Berkshire. The company manufactures and markets generic pharmaceutical products across more than 19 therapeutic areas—including erectile dysfunction, cardiovascular, antidiabetic, anti-inflammatory, antibiotic, gastrointestinal, and CNS categories—primarily in solid oral dosage forms (tablets and hard gelatin capsules). Its flagship commercial product is Tadalafil, sold under the Noumed own brand as well as under private-label arrangements with UK pharmacy chains such as Tesco and Numark, with strengths of 2.5mg, 5mg, 10mg, and 20mg. Operations are concentrated at a single MHRA-accredited, eco-friendly purpose-built facility that integrates the full pharmaceutical value chain: granulation and tablet compression in ISO-Class 8/Class D certified rooms, EU FMD-compliant high-speed packaging (four lines at 300-500 blisters per minute with Track and Trace serialization), a cGLP-compliant QC laboratory with Zone I–IVb stability chambers, and an MHRA-audited warehouse with cold storage and WDA. Regulatory affairs, pharmacovigilance (outsourced with a dedicated QPPV), and eCTD filing capabilities support registrations in regulated markets.

The business model combines three revenue streams: (1) direct sales of branded and private-label generic pharmaceutical products through UK pharmacy channels, distributed via a third-party logistics provider compliant with MHRA/GMP/GDP; (2) contract manufacturing services for multinational pharmaceutical partners from the Maidenhead facility and a network of CMOs in various geographies; and (3) global IP licensing, generating royalty income from other pharmaceutical companies commercializing Noumed's intellectual property. The go-to-market is B2B enterprise field sales targeting pharmacy chains, healthcare providers, and multinational pharmaceutical partners, supported by a professional website serving as the primary lead-generation mechanism. Customer segments include multinational pharmaceutical partners (primary), UK pharmacy retail chains and independents (primary), NHS and private healthcare providers, and end consumers purchasing pharmacy medicines. The company employs 51–100 staff and does not publicly disclose revenue. In December 2025, Noumed partially divested its Australian subsidiary (Noumed Pharmaceuticals Pty Ltd), with Sai Parenterals Limited acquiring a 74.6% equity stake, creating a cross-border strategic relationship spanning India, Singapore, Australia, and the UK.

Name

Noumed Life Sciences

Legal name

Noumed Life Sciences Limited

Website

https://noumed.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Short description

Noumed Life Sciences is a UK-based generic pharmaceutical manufacturer and CMO operating an MHRA-accredited facility in Maidenhead, producing tablets and capsules across 19+ therapeutic areas, with Tadalafil sold under Noumed, Tesco, and Numark brands through UK pharmacy channels.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oral Solid Dose (OSD) Generics (HLAIABAD)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

Keywords

• Generic pharmaceuticals
• Contract manufacturing
• Pharmaceutical packaging
• Regulatory affairs
• Pharmaceutical licensing

Headquarters

HQ city

Maidenhead

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Noumed manufactures and sells a diverse range of pharmaceutical products across multiple therapeutic segments including erectile dysfunction, antacids, antibiotics, anticonvulsants, anti-depressants, antidiarrheal, anti-fungal, antihistamine, antihyperglycemic, anti-inflammatory, antispasmodic, beta-blockers, cardiovascular, diabetic, gastrointestinal, hypertension, opiate, psychiatric, and vitamin products. Revenue is generated through the sale of finished pharmaceutical products.
2. Contract Manufacturing Services: Noumed has a network of CMOs (Contract Manufacturing Organisations) in various geographies and also provides contract manufacturing services from its own MHRA-accredited facility for diverse dosage forms. Revenue is generated through manufacturing fees for pharmaceutical products produced on behalf of partners.
3. Global IP Licensing: Noumed provides global IP licensing, allowing other pharmaceutical companies to use its intellectual property for product development and commercialization. Revenue is generated through licensing royalties.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Noumed Life Sciences is a UK-based pharmaceutical company that develops, manufactures, packages, and markets generic pharmaceutical products. The company operates an MHRA-accredited facility in Maidenhead offering integrated services spanning contract manufacturing of solid dosage forms (tablets and capsules), EU FMD-compliant packaging with serialization, quality control testing, warehousing, regulatory affairs with eCTD filings, pharmacovigilance, and global IP licensing.

Product overview

Noumed Life Sciences is a UK-based pharmaceutical company offering an integrated portfolio of products and contract manufacturing services. The company operates as a single unified offering combining manufacturing, packaging, quality control, warehousing, regulatory affairs, and pharmacovigilance services from its MHRA accredited facility in Maidenhead, UK. Product portfolio includes branded generic pharmaceuticals across multiple therapeutic areas: erectile dysfunction (Tadalafil in Noumed, Numark, and Tesco brands at 2.5mg, 5mg, 10mg, and 20mg strengths), antiarrhythmics (Amiodarone 200mg), and broad categories including antacids, antibiotics, anticonvulsants, antidepressants, antidiarrheals, antifungals, antihistamines, antihyperglycemics, anti-inflammatories, antispasmodics, beta-blockers, cardiovascular agents, diabetic treatments, gastrointestinal products, antihypertensives, opiates, psychiatric medications, and vitamins. The company differentiates through its in-house manufacturing capabilities for solid dosage forms (tablets, capsules), EU FMD compliant packaging with serialization, integrated quality systems, and network of external CMOs. Services include contract manufacturing (cGMP/FDA compliant), regulatory affairs support with eCTD filings, and outsourced pharmacovigilance.

Differentiator

Problem solved

Functional benefit

Brands

• Tadalafil (Noumed): Brand of Tadalafil 10mg tablets for erectile dysfunction, marketed under Noumed brand with risk minimisation materials.
• Tadalafil (Numark)
• Tadalafil (Tesco)

Products and services

• Tadalafil 10mg Tablets (Noumed Brand) Tadalafil 10mg tablets for erectile dysfunction marketed under the Noumed own brand. Classified as a P (Pharmacy) medicine, available without prescription through registered pharmacies. Includes pharmacy checklists, pharmacist guides, referral cards, and repeat purchase cards for patient risk minimisation.
• Tadalafil 10mg Tablets (Numark Brand) Tadalafil 10mg tablets distributed under the Numark pharmacy chain brand. Classified as a P (Pharmacy) medicine available through pharmacy channels. Includes pharmacy checklists and patient referral materials.
• Tadalafil 10mg Tablets (Tesco Brand) Tadalafil 10mg tablets distributed under the Tesco pharmacy brand. Classified as a P (Pharmacy) medicine with pharmacist checklist guides and pharmacy reference materials.
• Tadalafil Tablets (POM, 2.5mg/5mg/20mg) Tadalafil in multiple strengths (2.5mg, 5mg, 20mg) classified as POM (Prescription Only Medicine) for erectile dysfunction treatment.
• Amiodarone 200mg Tablets Amiodarone 200mg tablets for antiarrhythmic treatment, with patient alert card for healthcare professional information.
• Contract Manufacturing Services MHRA accredited manufacturing facility producing solid dosage forms including plain and coated tablets and hard gelatin capsules. Three independent granulation areas and two capsule manufacturing suites operating in ISO-Class 8/Class D certified rooms under cGMP and FDA guidelines. Supports R&D, feasibility trials, optimization trials, and small batch clinical trial manufacturing.
• Pharmaceutical Packaging Services On-site EU FMD compliant packaging with four high-speed packaging lines operating at 300-500 blisters per minute. Equipped with auto cartonators, Track and Trace, banding, and 2D barcoding capability. Unique identity encoding and serialization applied to every packaging unit in compliance with the EU Falsified Medicines Directive.
• Quality Control Laboratory Services Quality control facility with high-spec instrumentation, elaborate wet lab for chemical analysis, dedicated stability area with temperature and humidity chambers ranging from Zone I to Zone IVb. Supports manufacturing, product development, analytical method transfer, and routine testing of raw materials, finished products, and stability samples under cGLP.
• Warehouse and Logistics Services MHRA accredited purpose-built warehouse near Heathrow with temperature-controlled areas (2-8°C), clean room sampling facility, controlled dry storage, ERP-controlled labelling, WMS, and caged storage. UK distribution managed by a compliant 3PL following GMP and GDP guidelines. Holds WDA (Wholesale Dealer Authorisation).
• Regulatory Affairs Services Dedicated regulatory affairs team preparing CMCs, pre-clinical, clinical, product information, labelling, and patient information. Expertise in eCTD format regulatory filings in regulated markets, post-approval and product lifecycle management.
• Pharmacovigilance Services Outsourced pharmacovigilance activities with a dedicated QPPV (Qualified Person for Pharmacovigilance) to ensure compliance with all pharmacovigilance requirements and patient safety monitoring.
• Global IP Licensing Global IP licensing allowing other pharmaceutical companies to use Noumed's intellectual property for product development and commercialization. Revenue generated through licensing royalties.

Quantifiable outcome

• Manufacturing capability to run multiple dosage forms and flexible batch sizes from a single MHRA accredited UK facility
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature9 records

Partnerships

Two partnerships are on record, tiered core.

• Third-Party Logistics Provider (3PL)coreChannel Partner/ Reseller/ DistributorThe distribution of Noumed's finished products in the UK is managed by a reputable third-party logistics provider, fully compliant with MHRA and following GMP and GDP guidelines.
• Contract Manufacturing Organisation (CMO) NetworkcoreStrategic or Co-development PartnerNoumed has a network of CMOs in various geographies to manufacture diverse dosage forms in addition to what can be manufactured in-house. This extends Noumed's manufacturing capacity and geographic reach beyond its Maidenhead facility.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Almus Pharmaceuticals: UK-based generic pharmaceutical manufacturer supplying pharmacy retail and wholesale channels with a broad portfolio of generic medicines. Closely comparable to Noumed in product type (solid oral generics), customer base (UK pharmacy chains), and go-to-market.
• Ennogen Healthcare: UK-based generic pharmaceutical company marketing a wide range of generic medicines across multiple therapeutic areas. Comparable to Noumed in therapeutic breadth, UK focus, and private-company profile.
• Accord Healthcare: UK-based generic and specialty pharma manufacturer and supplier offering a broad generic portfolio across multiple therapeutic categories with strong UK and European distribution. Comparable in product scope, manufacturing-plus-distribution model, and customer base.
• Bristol Laboratories: UK-based pharmaceutical manufacturer producing generic medicines across multiple therapeutic areas, supplying UK and international markets. Similar to Noumed in being a UK-headquartered manufacturer serving B2B pharmacy and wholesale channels.
• Zentiva: European-focused generic pharmaceutical manufacturer with broad solid-dose portfolio across multiple therapeutic areas. Comparable to Noumed in product form, therapeutic breadth, and Europe-centric distribution, though at significantly larger scale.

Broad incumbents

• Aurobindo Pharma: India-based global generic pharmaceutical manufacturer with broad solid-dose portfolio and growing UK/European presence. Comparable in product space and increasingly in geographic overlap; far larger scale.
• Teva Pharmaceutical Industries: Global leader in generic pharmaceuticals with an extensive small-molecule portfolio across virtually all major therapeutic categories. Comparable in product space but materially larger and more diversified than Noumed, serving as the global incumbent benchmark.
• Viatris: Global generics and specialty manufacturer formed from Mylan-Upjohn combination, with broad solid-dose generic portfolio. Operates in the same small-molecule generic space as Noumed but at much larger scale and geographic reach.
• Sandoz (Novartis): One of the world's largest generic and biosimilar manufacturers with a broad small-molecule portfolio. Comparable product category to Noumed, operating at vastly greater scale with global manufacturing and distribution.

Emerging players

• Sai Parenterals Limited: India-based sterile injectable pharmaceutical manufacturer that recently acquired 74.6% of Noumed's Australian subsidiary. Related as Noumed's strategic parent and a peer in pharmaceutical manufacturing with focus on injectable dosage forms — comparable through the parent-subsidiary linkage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Noumed_Life
• Facebookfacebook.com/NoumedLifeSciences
• LinkedInlinkedin.com/company/noumedlifesciences

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Noumed Life Sciences